1. Home
  2. BMEA
  3. BMEA News

Latest Biomea Fusion Inc. (BMEA) News on September 13, 2025

Biomea Fusion announces presentation of icovamenib preclinical, clinical data
BMEA

TipRanks

3 months ago

Biomea Fusion announces presentation of icovamenib preclinical, clinical data

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
BMEA

GlobeNewswire

3 months ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

BMEA

MT Newswires

3 months ago

Top Midday Decliners

BMEA

MT Newswires

3 months ago

Biomea Says Preclinical Results Show 'Robust' Weight Loss From Investigational Drug

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
BMEA

GlobeNewswire

3 months ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

BMEA

MT Newswires

3 months ago

Update: Biomea Fusion Prices $40 Million Securities Offering; Shares Down Pre-Bell

BMEA

MT Newswires

3 months ago

Biomea Fusion Prices $40 Million Offering of Securities

Biomea Fusion Announces Pricing of Public Offering of Securities
BMEA

GlobeNewswire

3 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

BMEA

MT Newswires

3 months ago

Biomea Fusion Launches Public Offering of Securities; Shares Fall After Hours

Biomea Fusion Announces Proposed Public Offering of Securities
BMEA

GlobeNewswire

3 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
BMEA

GlobeNewswire

3 months ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

3 Promising Penny Stocks With Market Caps Over $90M
BMEA

Simply Wall St.

3 months ago

3 Promising Penny Stocks With Market Caps Over $90M

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know
BMEA

Zacks

3 months ago

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know

Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
BMEA

GlobeNewswire

4 months ago

Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
BMEA

GlobeNewswire

4 months ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
BMEA

Zacks

5 months ago

After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

5 months ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
BMEA

Zacks

5 months ago

After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
BMEA

GlobeNewswire

5 months ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
BMEA

Zacks

5 months ago

After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)

BMEA

MT Newswires

6 months ago

Biomea Fusion Appoints Michael Hitchcock Interim CEO

Biomea Fusion Announces Leadership Transition
BMEA

GlobeNewswire

6 months ago

Biomea Fusion Announces Leadership Transition

Biomea Fusion announces presentation of icovamenib preclinical, clinical data
BMEA

TipRanks

6 months ago

Biomea Fusion announces presentation of icovamenib preclinical, clinical data

Freightos And 2 Other Penny Stocks Worth Watching
BMEA

Simply Wall St.

6 months ago

Freightos And 2 Other Penny Stocks Worth Watching

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
BMEA

GlobeNewswire

6 months ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Biomea Fusion Insiders Recover Some Losses, Which Stand At US$91k
BMEA

Simply Wall St.

6 months ago

Biomea Fusion Insiders Recover Some Losses, Which Stand At US$91k

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

6 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
BMEA

GlobeNewswire

7 months ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Promising US Penny Stocks To Watch In February 2025
BMEA

Simply Wall St.

7 months ago

Promising US Penny Stocks To Watch In February 2025

Biomea Fusion, Inc. (NASDAQ:BMEA) is a favorite amongst institutional investors who own 51%
BMEA

Simply Wall St.

7 months ago

Biomea Fusion, Inc. (NASDAQ:BMEA) is a favorite amongst institutional investors who own 51%

Biomea Fusion to Become a Diabetes & Obesity Medicines Company
BMEA

GlobeNewswire

8 months ago

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

3 US Penny Stocks With Market Caps Up To $2B
BMEA

Simply Wall St.

8 months ago

3 US Penny Stocks With Market Caps Up To $2B

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
BMEA

GlobeNewswire

8 months ago

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Here’s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10
BMEA

Insider Monkey

8 months ago

Here’s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BMEA

GlobeNewswire

8 months ago

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
BMEA

Benzinga

9 months ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
BMEA

GlobeNewswire

9 months ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
BMEA

GlobeNewswire

9 months ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
BMEA

GlobeNewswire

9 months ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

BMEA

MT Newswires

9 months ago

Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
BMEA

GlobeNewswire

9 months ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
BMEA

GlobeNewswire

9 months ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

9 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
BMEA

GlobeNewswire

10 months ago

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
BMEA

Simply Wall St.

10 months ago

We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

10 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
BMEA

GlobeNewswire

10 months ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
BMEA

GlobeNewswire

10 months ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
BMEA

GlobeNewswire

a year ago

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy
BMEA

GlobeNewswire

a year ago

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Morning Movers: Arcadium Lithium surges after deal to be acquired
BMEA

TipRanks

a year ago

Morning Movers: Arcadium Lithium surges after deal to be acquired

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
BMEA

GlobeNewswire

a year ago

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
BMEA

Simply Wall St.

a year ago

Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares

BMEA

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/02/2024

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
BMEA

GlobeNewswire

a year ago

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
BMEA

Benzinga

a year ago

FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate

Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
BMEA

Pharmaceutical Technology

a year ago

Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials

BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
BMEA

Zacks

a year ago

BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies

BMEA

MT Newswires

a year ago

Truist Securities Upgrades Biomea Fusion to Buy From Hold, Price Target is $54

BMEA

MT Newswires

a year ago

Biomea Fusion Shares Gain After US FDA Lifts Clinical Hold on Phase 1/2 Trials

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
BMEA

GlobeNewswire

a year ago

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

With 51% institutional ownership, Biomea Fusion, Inc. (NASDAQ:BMEA) is a favorite amongst the big guns
BMEA

Simply Wall St.

a year ago

With 51% institutional ownership, Biomea Fusion, Inc. (NASDAQ:BMEA) is a favorite amongst the big guns

Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet
BMEA

Zacks

a year ago

Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

a year ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
BMEA

GlobeNewswire

a year ago

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating?
BMEA

Insider Monkey

a year ago

Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating?

Why Are Hedge Funds Shorting Biomea Fusion, Inc. (BMEA)?
BMEA

Insider Monkey

a year ago

Why Are Hedge Funds Shorting Biomea Fusion, Inc. (BMEA)?

Franco Valle Bought 42% More Shares In Biomea Fusion
BMEA

Simply Wall St.

a year ago

Franco Valle Bought 42% More Shares In Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays
BMEA

Insider Monkey

a year ago

Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
BMEA

CNW Group

a year ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
BMEA

PR Newswire

a year ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
BMEA

Business Wire

a year ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts
BMEA

AFP

a year ago

New Zealand scraps plan to tax livestock burps, farts

BMEA

Business Wire

a year ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
BMEA

The Wall Street Journal

a year ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool
BMEA

Bloomberg

a year ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024
BMEA

Simply Wall St.

a year ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Biomea Fusion Crashes 63% After FDA Puts Diabetes Treatment Studies On Hold
BMEA

Investor's Business Daily

a year ago

Biomea Fusion Crashes 63% After FDA Puts Diabetes Treatment Studies On Hold

BMEA

MT Newswires

a year ago

Top Midday Decliners

BMEA

MT Newswires

a year ago

Piper Sandler Adjusts Price Target on Biomea Fusion to $10 From $45, Maintains Overweight Rating

Biomea Fusion Crashes 67% After FDA Puts Diabetes Treatment Studies On Hold
BMEA

Investor's Business Daily

a year ago

Biomea Fusion Crashes 67% After FDA Puts Diabetes Treatment Studies On Hold

BMEA

MT Newswires

a year ago

Scotiabank Cuts Price Target on Biomea Fusion to $21 From $41, Maintains Sector Outperform Rating

BMEA

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

BMEA

MT Newswires

a year ago

Top Premarket Decliners

BMEA

MT Newswires

a year ago

Update: Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold; Shares Plummet Premarket

FDA places full clinical hold on Biomea Fusion’s diabetes trials of BMF-219
BMEA

Clinical Trials Arena

a year ago

FDA places full clinical hold on Biomea Fusion’s diabetes trials of BMF-219

BMEA

MT Newswires

a year ago

Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
BMEA

GlobeNewswire

a year ago

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

a year ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BMEA

MT Newswires

a year ago

Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
BMEA

GlobeNewswire

a year ago

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

BMEA

MT Newswires

a year ago

Oppenheimer Adjusts Biomea Fusion Price Target to $60 From $70, Maintains Outperform Rating

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
BMEA

Simply Wall St.

a year ago

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
BMEA

GlobeNewswire

a year ago

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

a year ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

a year ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
BMEA

GlobeNewswire

a year ago

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
BMEA

GlobeNewswire

a year ago

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
BMEA

GlobeNewswire

2 years ago

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BMEA

GlobeNewswire

2 years ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Share on Social Networks: